Courses

Improving Systematic Monitoring for Glucocorticoid Adverse Events to Guide Appropriate Use of Steroid-Sparing Therapy in Patients with gMG
Neurology

Improving Systematic Monitoring for Glucocorticoid Adverse Events to Guide Appropriate Use of Steroid-Sparing Therapy in Patients with gMG

Myasthenia gravis is one of the oldest recognized autoimmune neurologic diseases, but practice-changing clinical trials remain challenging despite greater knowledge of pathophysiology. Both incidence and prevalence of the disease have increased over the years because of greater awareness of MG, better application of diagnostic testing, and better quality of epidemiologic studies. Corticosteroids were introduced as treatment for MG in the 1950s ...
View Course

Clinical Update on Anemia of Chronic Kidney Disease: Improving Outcomes for All Patients
Nephrology

Clinical Update on Anemia of Chronic Kidney Disease: Improving Outcomes for All Patients

Anemia is a common complication in CKD (aCKD) and is associated with a reduced quality of life and increased morbidity and mortality. The mechanisms involved in aCKD are diverse and complex. They include a decrease in endogenous erythropoietin production, absolute and/or functional iron deficiency, and inflammation with increased hepcidin levels, among others. Patients are most commonly managed with oral or ...
View Course
Optimizing Echocardiographic and CMR Assessment in the Diagnosis and Management of Hypertrophic Cardiomyopathy
Cardiology

Optimizing Echocardiographic and CMR Assessment in the Diagnosis and Management of Hypertrophic Cardiomyopathy

This CME program, derived from content presented at the European Association of Cardiovascular Imaging Annual Congress EACVI 2023 in Barcelona, Spain, will highlight how to optimize echocardiographic and CMR assessment in the diagnosis and management of hypertrophic cardiomyopathy. In hypertrophic cardiomyopathy, multimodality imaging is crucial to confirm diagnosis, assess for presence and mechanism of left ventricular outflow tract obstruction, and ...
View Course

The Advancing Role of PARP Inhibitor Combination Therapies to Improve Outcomes for Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Oncology

The Advancing Role of PARP Inhibitor Combination Therapies to Improve Outcomes for Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC)

This CME program, derived from content presented at the AACR Annual Meeting 2023 in Orlando, FL, will highlight the advancing role of PARP inhibitor combination therapies to improve outcomes for patients with metastatic castration-resistant prostate cancer (mCRPC). The expert faculty, led by Dr. Alan Tan, will first review the science, mechanism of action, and clinical rationale for PARP-inhibitors and PARP-inhibitor/androgen ...
View Course

The New Era of Inflammatory Disease Management Through the Application of Biosimilar Therapeutics
Gastroenterology, Immunology, Rheumatology

The New Era of Inflammatory Disease Management Through the Application of Biosimilar Therapeutics

While biosimilar therapeutics have been widely available for some time for the treatment inflammatory conditions, many pharmacists, managed care professionals, and other healthcare providers have not had a recent opportunity to investigate data showing the interchangeable safety and efficacy alignment between approved biosimilar therapeutics and their less accessible referent medications. In addition to interchangeability, concepts involving extrapolation and the shifting ...
View Course
Update on New and Emerging CD-20 Targeted Therapeutics for the Treatment of Patients with Multiple Sclerosis
Neurology

Update on New and Emerging CD-20 Targeted Therapeutics for the Treatment of Patients with Multiple Sclerosis

This CME program, derived from content presented at the Pre-ACTRIMS Advanced Curriculum for Multiple Sclerosis 2023 CME Course in San Diego, California, will highlight new and emerging CD-20 targeted therapeutics for the treatment of patients with multiple sclerosis (MS). The expert faculty, Dr. Mark Freedman, will first review current clinical trial data for CD-20 targeted therapies to improve long-term patient ...
View Course

Accurate and Effective Imaging in the Diagnosis and Management of Hypertrophic Cardiomyopathy: A Practical Approach
Cardiology

Accurate and Effective Imaging in the Diagnosis and Management of Hypertrophic Cardiomyopathy: A Practical Approach

Accurate diagnosis is vital for the successful management of patients with HCM.  Mistakes and delays in diagnosis are common. Hypertrophic cardiomyopathy commonly "masquerades" as asthma, anxiety, mitral prolapse, and coronary artery disease. However, once properly diagnosed, patients with HCM can be effectively managed to improve both symptoms and survival. Today, the diagnosis of HCM relies on the identification of increased ...
View Course
Anti-CD19 Therapeutics to Manage Patients with Anti-AQP4 Antibody Positive Neuromyelitis Optics Spectrum Disorder
Neurology

Anti-CD19 Therapeutics to Manage Patients with Anti-AQP4 Antibody Positive Neuromyelitis Optics Spectrum Disorder

This CME program, derived from content presented at the Pre-ACTRIMS Advanced Curriculum for Multiple Sclerosis 2023 CME Course in San Diego, California, will highlight the use of anti-CD19 therapeutics to manage patients with anti-AQP4 antibody positive neuromyelitis optica spectrum disorder (NMOSD). The expert faculty, Prof. Hans-Peter Hartung, will first analyze the methodologies for a timely and accurate diagnosis of NMOSD ...
View Course

Advances in the Management of Patients with Diabetic Kidney Disease in the Setting of Type 2 Diabetes
Nephrology

Advances in the Management of Patients with Diabetic Kidney Disease in the Setting of Type 2 Diabetes

New, actionable data on the use of sodium-glucose co-transporter-2 (SGLT2) inhibitors was released at several major meetings in 2022, culminating in November at ASN/Kidney Week that herald signal advances in the management of DKD/T2D. These new data and an expert contextualization of their role in contemporary practice is the basis of this webcast. Nephrologists, diabetologists, other internists, primary care providers, ...
View Course
Specific Reversal of Anti-Factor Xa DOAC Anticoagulation: Incorporating Latest Data into Practice and Institutional Protocols
Cardiology, Neurology

Specific Reversal of Anti-Factor Xa DOAC Anticoagulation: Incorporating Latest Data into Practice and Institutional Protocols

Severe and life-threatening hemorrhage in patients receiving anti-FXa DOACs is unusual; especially for the most-feared bleeding complication, ICH, events are significantly less common than for patients on vitamin K antagonists (VKA).  Still, these events occur, and there is a need for specific, timely, evidence-guided, and multimodal management of DOAC-treated patients with hemorrhage to avoid worsening morbidity, excessive cost and length ...
View Course